Kezar Life Sciences

Please note: The information displayed on this page might be outdated.
Kezar Life Sciences: Clinical stage biotechnology company pioneering first-in-class, small molecule therapies designed to inhibit multiple disease-driving cellular pathways by targeting key intracellular proteins. The Company is advancing two differentiated therapeutic approaches: Selective Immunoproteasome Inhibition, for the treatment of autoimmune diseases through immune modulation versus direct immunosuppression; and Protein Secretion Inhibition, halting the secretion of target proteins that contribute to a range of cancers and autoimmune diseases. Lead candidate, zetomipzomib (KZR-616), a selective immunoproteasome inhibitor, is being evaluated in Phase 2 clinical trials for lupus nephritis and autoimmune hepatitis, and KZR-261, a first-in-class inhibitor of the Sec61 translocon developed using the Company’s novel discovery Protein Secretion Inhibition Platform, is undergoing a Phase 1 clinical trial for the treatment of advanced/metastatic solid tumors.
Based in...
US - Pacific
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Oncology
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Small Molecule
4000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States

Company Participants at Solebury 1x1 Management Access Event 2023

  • John Fowler, CEO, Co-Founder
  • Marc L. Belsky, Chief Financial Officer
  • Nick Mordwinkin , PhD, Chief Business Officer
  • Noreen Henig, MD, CMO

Top 10 Holders of Kezar Life Sciences Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Avidity Partners Management LP 9.92 6,782,400 24.82 13F 12/31/22
OrbiMed Advisors LLC 6.70 4,584,322 16.78 13F 12/31/22
State Street Corp. 6.22 4,253,960 15.57 13F 12/31/22
Suvretta Capital Management LLC 5.12 3,504,264 12.83 13F 12/31/22
Bellevue Asset Management AG 4.43 3,031,000 11.09 13F 12/31/22
Vanguard Group, Inc. (Subfiler) 4.30 2,943,274 10.77 13F 12/31/22
The Vanguard Group, Inc. 4.28 2,934,996 10.74 Funds 2/28/23
Millennium Management LLC 4.24 2,896,495 10.60 13F 12/31/22
BlackRock Fund Advisors 3.66 2,504,325 9.17 13F 12/31/22
CHI Advisors LLC 2.76 1,889,451 6.92 13F 12/31/22
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.